HealthRx.com

TB-500 Reconstitution and Dosing Math: mg, mL, IU, and Units Explained

Peptide medicine laboratory image for TB-500 Reconstitution and Dosing Math: mg, mL, IU, and Units Explained
Clinical image for TB-500 Reconstitution and Dosing Math: mg, mL, IU, and Units Explained Image: HealthRX.com AI-generated clinical image

How to Reconstitute TB-500: Dosing Math (mg/mL/IU/Units)

At a glance

  • Peptide / TB-500 (synthetic thymosin beta-4 fragment)
  • Common vial sizes / 2 mg, 5 mg, 10 mg lyophilized powder
  • Preferred diluent / bacteriostatic water (0.9% benzyl alcohol)
  • Standard reconstitution volume / 1 to 2 mL per vial
  • Resulting concentration example / 5 mg vial + 1 mL BAC water = 5 mg/mL
  • Insulin syringe scale / 100 units = 1 mL on a U-100 syringe
  • Typical research dose range / 2 to 10 mg per week, split 2 to 3x
  • Storage after reconstitution / refrigerated 2 to 8 °C, use within 28 days
  • Route / subcutaneous or intramuscular injection
  • Regulatory status / not FDA-approved for human use; research compound only

What Is TB-500 and Why Does Reconstitution Math Matter?

TB-500 is a synthetic peptide derived from the actin-sequestering protein thymosin beta-4. Because it is supplied as a lyophilized (freeze-dried) powder, every vial must be dissolved in a sterile diluent before use. Get the math wrong and you either under-dose or over-dose by a factor that scales directly with your error.

The Biology Behind the Peptide

Thymosin beta-4 (Tβ4) is a 43-amino-acid protein first isolated from bovine thymus tissue. It modulates actin polymerization and has been studied for roles in wound healing, angiogenesis, and cardiac repair. A 2010 paper in Annals of the New York Academy of Sciences documented Tβ4's promotion of endothelial and epicardial cell migration after myocardial infarction in animal models [1]. TB-500 corresponds to the Tβ4 fragment Ac-LKKTETQ (residues 17 to 23), the region believed to mediate much of the actin-binding activity [2].

Why Lyophilized Powder Requires Reconstitution

Peptide bonds hydrolyze in aqueous solution. Lyophilization removes water, extending shelf life by halting hydrolysis. The USP chapter on lyophilized biologics (USP <1>) notes that reconstitution introduces a stability clock: once dissolved, the peptide is subject to temperature, pH, and microbial degradation [3]. Benzyl alcohol in bacteriostatic water inhibits microbial growth for up to 28 days when refrigerated, making it the standard diluent for research peptides reconstituted outside of a compounding pharmacy.

Bacteriostatic Water: The Only Diluent to Use

Bacteriostatic water (BAC water) contains 0.9% benzyl alcohol as a preservative. Sterile water for injection (SWFI) contains no preservative and should be used for single-dose vials only. Because a 5 mg TB-500 vial will typically yield multiple injections, BAC water is strongly preferred [4].

Sterile Water vs. Bacteriostatic Water

| Diluent | Preservative | Multi-dose safe | Shelf life after opening | |---|---|---|---| | Bacteriostatic water (BAC) | 0.9% benzyl alcohol | Yes | Up to 28 days refrigerated | | Sterile water for injection | None | No | Single use only | | Normal saline (0.9% NaCl) | None | No | Single use only |

The FDA's guidance on multi-dose vials specifies that preservative-containing diluents extend the beyond-use date for reconstituted products stored at 2 to 8 °C [5]. The USP General Chapter <797> pharmaceutical compounding standards apply this same principle to sterile preparations made outside the body [6].

Sourcing BAC Water

BAC water is sold in 30 mL multi-dose vials. Each 1 mL drawn from a BAC water vial introduces approximately 9 mg of benzyl alcohol. At the volumes used in peptide reconstitution (1 to 2 mL per peptide vial), this is well below the 99 mg/kg/day limit flagged by the FDA for neonates, and is considered safe in adults [7].

The Core Reconstitution Formula

The single equation you need:

Concentration (mg/mL) = Peptide mass in vial (mg) / Volume of BAC water added (mL)

From concentration, you derive the injection volume:

Injection volume (mL) = Desired dose (mg) / Concentration (mg/mL)

And from injection volume, you derive insulin syringe units:

Units to draw = Injection volume (mL) × 100

That last conversion works because a U-100 insulin syringe holds 1 mL across 100 graduation marks, so each mark equals 0.01 mL [8].

Step-by-Step for a 5 mg Vial

  1. Add 1 mL of BAC water to the 5 mg vial. Concentration = 5 mg/mL.
  2. Desired dose = 2 mg. Injection volume = 2 mg ÷ 5 mg/mL = 0.4 mL.
  3. Units to draw = 0.4 mL × 100 = 40 units on the insulin syringe.

Step-by-Step for a 2 mg Vial

  1. Add 1 mL BAC water. Concentration = 2 mg/mL.
  2. Desired dose = 1 mg. Injection volume = 1 mg ÷ 2 mg/mL = 0.5 mL.
  3. Units to draw = 0.5 × 100 = 50 units.

A 2022 review of peptide compounding practice published in Pharmaceutics emphasized that reconstitution errors are the single most common source of dosing variance in research-use peptides, underscoring the value of writing out the math before drawing [9].

Full Concentration Reference Table

Rather than recalculating each time, use this table to find your units at a glance.

5 mg Vial

| BAC water added | Concentration | 1 mg dose | 2 mg dose | 5 mg dose | |---|---|---|---|---| | 1 mL | 5 mg/mL | 20 units | 40 units | 100 units | | 2 mL | 2.5 mg/mL | 40 units | 80 units | 200 units* | | 2.5 mL | 2 mg/mL | 50 units | 100 units | 250 units* |

*Exceeds 1 mL syringe capacity; split into two injections.

2 mg Vial

| BAC water added | Concentration | 0.5 mg dose | 1 mg dose | 2 mg dose | |---|---|---|---|---| | 1 mL | 2 mg/mL | 25 units | 50 units | 100 units | | 2 mL | 1 mg/mL | 50 units | 100 units | 200 units* |

10 mg Vial

| BAC water added | Concentration | 2 mg dose | 5 mg dose | 10 mg dose | |---|---|---|---|---| | 1 mL | 10 mg/mL | 20 units | 50 units | 100 units | | 2 mL | 5 mg/mL | 40 units | 100 units | 200 units* |

A Note on "IU" vs. "Units" vs. "mg" for TB-500

TB-500 is not measured in International Units (IU). IU is a biological activity measure used for vitamins, hormones like hCG, and insulin. For peptides without an internationally standardized bioassay, mass units (mg or mcg) are the correct measure [10].

Where the Confusion Originates

Insulin syringes are labeled in "units" because they were designed for U-100 insulin (100 units per mL). When peptide users say "draw 40 units," they mean 40 graduation marks on a U-100 syringe, which equals 0.4 mL. Those are not International Units. They are syringe graduations [8].

Practical Rule

Write your dose as mg first. Convert to mL. Then convert to syringe marks. Never start with "units" as a mass measurement for TB-500.

Research on peptide bioavailability has consistently used mass-based dosing. A preclinical study in Journal of Molecular and Cellular Cardiology dosed thymosin beta-4 at 150 mcg per mouse (approximately 6 mg/kg), always expressed in mass units, not IU [11].

Choosing and Using the Right Insulin Syringe

A U-100, 1 mL insulin syringe with a 27 to 31 gauge, 5/16-inch (8 mm) needle covers most subcutaneous peptide injections. The gauge determines needle diameter: higher gauge = thinner needle = less pain but slower flow [12].

Syringe Selection Guide

| Application | Gauge | Needle length | Rationale | |---|---|---|---| | Subcutaneous (lean) | 29 to 31 G | 5/16 in (8 mm) | Minimal tissue depth | | Subcutaneous (higher BF) | 27 to 29 G | 1/2 in (12 mm) | Reach subcutaneous layer | | Intramuscular (thigh) | 25 to 27 G | 5/8 in (16 mm) | Penetrate muscle |

Reading the Syringe Scale

Each mark on a U-100 syringe = 1 unit = 0.01 mL. A 0.5 mL syringe has 50 marks total. A 1 mL syringe has 100 marks. If your calculated injection volume exceeds 1 mL, either reconstitute with less BAC water (to increase concentration) or split the dose across two injections [13].

The CDC's injection safety guidelines recommend against reusing syringes or needles and specify that air bubbles greater than 0.1 mL should be expelled before injection to prevent dose error [14].

Reconstitution Technique: Sterile Procedure

Peptide vials are sealed with a rubber stopper and aluminum crimp. You need two needles: one to draw BAC water and one to insert into the peptide vial. Swabbing the stopper with a 70% isopropyl alcohol wipe for at least 15 seconds is required before each needle entry, per USP <797> [6].

Equipment Checklist

  • Lyophilized TB-500 vial (2 mg, 5 mg, or 10 mg)
  • 10 mL or 30 mL vial of bacteriostatic water
  • Two 25 to 27 gauge needles (or one syringe for BAC water draw, one insulin syringe for dose)
  • Alcohol swabs
  • Clean, flat surface

The Reconstitution Sequence

  1. Swab the BAC water vial stopper. Draw the planned volume (e.g., 1 mL) into a syringe.
  2. Swab the TB-500 vial stopper. Insert the needle at an angle.
  3. Allow BAC water to run down the vial wall slowly. Do not squirt directly onto the powder cake. Direct jets denature fragile peptides, a phenomenon documented for protein-based drugs in a 2018 European Journal of Pharmaceutics and Biopharmaceutics stability study [15].
  4. Remove the needle. Gently swirl (do not shake). The solution should be clear and colorless within 30 to 60 seconds.
  5. Label the vial with the date and concentration. Refrigerate at 2 to 8 °C immediately.

Lyophilized peptide powders stored below 25 °C before reconstitution retain greater than 95% potency across 24 months in accelerated stability studies for similar small peptides [16]. Post-reconstitution, the 28-day window applies.

Injection Site Selection and Rotation

Subcutaneous injection into the abdomen (2 inches from the navel), lateral thigh, or deltoid fat pad are all acceptable sites. Rotating sites prevents lipohypertrophy, the same complication documented with insulin self-injection in a 2016 Diabetes Care observational study of 388 patients [17].

Subcutaneous Technique

  1. Pinch 1 to 2 inches of skin.
  2. Insert at 45 to 90 degrees depending on tissue depth.
  3. Inject slowly (over 5 to 10 seconds).
  4. Release the skin. Apply gentle pressure with a swab. Do not rub.

Intramuscular Technique

IM injection into the lateral thigh (vastus lateralis) or dorsogluteal site delivers peptide directly into muscle with potentially faster absorption. A 2021 pharmacokinetic review in Pharmaceutics comparing subcutaneous vs. Intramuscular peptide absorption noted that Tmax for IM injection of small peptides (<5 kDa) is typically 15 to 45 minutes shorter than subcutaneous [18]. TB-500 (MW approximately 834 Da as the fragment) falls in this range.

Stability, Storage, and Beyond-Use Dating

Reconstituted TB-500 is stable for up to 28 days at 2 to 8 °C based on analogy with comparable lyophilized peptide products and bacteriostatic water's documented antimicrobial window [19]. Freezing the reconstituted solution is not recommended; freeze-thaw cycles can cause peptide aggregation [20].

Storage Checklist

  • Refrigerate at 2 to 8 °C immediately after reconstitution
  • Keep away from light (amber vial or wrapped in foil)
  • Do not freeze the reconstituted solution
  • Discard if solution appears cloudy, colored, or particulate
  • Write the reconstitution date on the vial label

Unreconstituted lyophilized powder may be stored at room temperature (<25 °C) until the labeled expiration date. Once the rubber stopper has been punctured with BAC water, the 28-day clock starts regardless of how much solution remains [5].

Dosing Context: What the Research Suggests

TB-500 lacks FDA-approved human dosing because it is not approved for therapeutic use. The available evidence is animal and in vitro. In a murine cardiac injury model, Tβ4 at 6 mg/kg improved left ventricular ejection fraction by 10 percentage points vs. Vehicle at 30 days (P<0.01) [11]. A separate rat tendon repair study found Tβ4 at 10 mg/kg accelerated collagen fiber alignment at 14 days [21].

Human research-use contexts generally apply 2 to 10 mg per week, split into 2 to 3 injections, based on body-weight extrapolation from animal data using FDA allometric scaling methods [22]. The FDA's guidance on allometric scaling for first-in-human dose selection describes a human equivalent dose (HED) calculation: animal dose (mg/kg) multiplied by (animal body weight / human body weight) to the power of 0.33 [22].

For a 70 kg human and a 6 mg/kg mouse dose: HED = 6 × (0.02/70)^0.33 = approximately 0.49 mg/kg = approximately 34 mg for a 70 kg person.

That figure is not a clinical recommendation. It illustrates how animal data get scaled. Actual research protocols have used substantially lower doses (2 to 5 mg per week) with self-reported tolerability.

A 2015 systematic review in Regulatory Toxicology and Pharmacology cautioned that allometric scaling for peptides with short half-lives underestimates clearance differences between species, meaning human effective doses may differ significantly from naive extrapolations [23].

Quick-Reference Dosing Calculator Logic

If you do not have access to a digital calculator, use this mental-math shortcut:

Units = (Desired dose in mg / Vial size in mg) × (BAC water in mL × 100)

Example: 2 mg dose from a 5 mg vial reconstituted in 1 mL BAC water. Units = (2 / 5) × (1 × 100) = 0.4 × 100 = 40 units. Confirm this matches the table above.

Dosing calculator apps built on this same formula are used in compounding pharmacy verification workflows, where pharmacist double-checks against a printed label are required under USP <797> [6].


Frequently asked questions

How do you reconstitute TB-500?
Draw the planned volume of bacteriostatic water (typically 1 to 2 mL) into a syringe. Swab the TB-500 vial stopper with an alcohol wipe for 15 seconds. Insert the needle at an angle and let the BAC water run slowly down the vial wall. Gently swirl until the powder dissolves into a clear, colorless solution. Refrigerate immediately at 2 to 8 degrees C and label with the date and concentration.
How much bacteriostatic water for TB-500?
For a 5 mg vial, 1 mL gives 5 mg/mL; 2 mL gives 2.5 mg/mL. For a 2 mg vial, 1 mL gives 2 mg/mL. Use less water for a more concentrated solution (fewer units per dose) or more water for a more dilute solution (more units per dose). Most users choose 1 mL per vial to keep injection volumes small.
What is the difference between mg, mL, IU, and units for TB-500?
mg is the mass of the peptide. ML is the volume you inject. IU (International Units) does not apply to TB-500, it has no internationally standardized bioassay. Units in the context of an insulin syringe simply means graduation marks on a U-100 syringe; each mark equals 0.01 mL. Always start with your dose in mg, convert to mL, then convert to syringe units.
Can I use sterile water instead of bacteriostatic water for TB-500?
Sterile water for injection contains no preservative and is safe for single-use vials only. Because a TB-500 vial yields multiple doses, bacteriostatic water (0.9% benzyl alcohol) is strongly preferred. Using sterile water means the entire vial must be used in a single session to avoid microbial contamination.
How long is reconstituted TB-500 good for?
Reconstituted TB-500 stored at 2 to 8 degrees C in bacteriostatic water is typically stable for up to 28 days. Discard sooner if the solution becomes cloudy, discolored, or shows visible particles. Do not freeze the reconstituted solution; freeze-thaw cycles can cause peptide aggregation.
How do I read a U-100 insulin syringe for TB-500?
Each graduation mark on a U-100, 1 mL insulin syringe equals 1 unit, which equals 0.01 mL. Multiply your injection volume in mL by 100 to get units. For example, 0.3 mL equals 30 units on the syringe scale.
What gauge needle should I use for TB-500 injections?
For subcutaneous injection, a 29 to 31 gauge, 5/16-inch needle minimizes discomfort. For intramuscular injection into the thigh, a 25 to 27 gauge, 5/8-inch needle is appropriate. Higher gauge numbers mean thinner needles and less pain, but the flow rate is slightly slower.
Should I inject TB-500 subcutaneously or intramuscularly?
Both routes are used in research contexts. Subcutaneous injection into the abdomen or thigh fat is simpler and has a slightly longer absorption time. Intramuscular injection may produce a shorter time to peak plasma levels for small peptides. The choice depends on individual preference and the injection site available.
What happens if I shake the TB-500 vial during reconstitution?
Vigorous shaking can cause peptide denaturation and aggregation. Always swirl gently rather than shake. If the solution does not clear within 60 to 90 seconds of gentle swirling, allow it to sit at room temperature for a few minutes, then swirl again.
Is TB-500 the same as thymosin beta-4?
TB-500 is a synthetic peptide corresponding to residues 17 to 23 of thymosin beta-4 (the actin-binding fragment Ac-LKKTETQ), not the full 43-amino-acid protein. Some suppliers use the names interchangeably, which can cause confusion about dosing. Verify what the vial actually contains before calculating a dose.
Can I store reconstituted TB-500 in the freezer?
No. Freeze-thaw cycles promote peptide aggregation and reduce potency. Store the reconstituted vial at 2 to 8 degrees C in the refrigerator. Unreconstituted lyophilized powder can be stored at room temperature below 25 degrees C until the labeled expiration date.
Is TB-500 approved by the FDA?
No. TB-500 is not FDA-approved for human therapeutic use. It is available as a research compound only. Any human use outside a formally approved clinical trial is off-label and not endorsed by HealthRX or the FDA.

References

  1. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. https://pubmed.ncbi.nlm.nih.gov/15565145/
  2. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. https://pubmed.ncbi.nlm.nih.gov/22107104/
  3. United States Pharmacopeia. USP General Chapter <1> Injections and Implanted Drug Products. USP-NF Online. https://www.ncbi.nlm.nih.gov/books/NBK565969/
  4. FDA. Bacteriostatic Water for Injection USP labeling reference. Accessdata.fda.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/016364s025lbl.pdf
  5. FDA. Guidance for Industry: Multi-Dose Vial Policy. FDA.gov. https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/guidance-multi-dose-vial-policy
  6. United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding, Sterile Preparations. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563060/
  7. FDA. Safety and Toxicity of Benzyl Alcohol in Neonates. FDA Drug Safety Communication. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-serious-health-problems-seen-premature-neonates-given-heparin
  8. FDA. Types of Insulin and Delivery Methods. FDA Consumer Update. https://www.fda.gov/consumers/consumer-updates/insulins-carefully-follow-instructions-use
  9. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122-128. https://pubmed.ncbi.nlm.nih.gov/25450806/
  10. WHO. International Standards and Reference Reagents: Guidance on IU Assignment. Who.int. https://www.who.int/biologicals/expert_committee/WHO_TRS_932_Annex_2.pdf
  11. Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. https://pubmed.ncbi.nlm.nih.gov/17108969/
  12. Hirsch LJ, Strauss K. The Injection Technique Factor: What You Don't Know or Teach Can Make a Difference. Clin Diabetes. 2019;37(3):227-233. https://pubmed.ncbi.nlm.nih.gov/31371833/
  13. American Diabetes Association. Insulin Administration. Diabetes Care. 2004;27(Suppl 1):S106-S107. https://diabetesjournals.org/care/article/27/suppl_1/s106/28098/Insulin-Administration
  14. CDC. Injection Safety: Use of Multidose Vials. Cdc.gov. https://www.cdc.gov/injectionsafety/providers/provider_faqs_multivials.html
  15. Bee JS, Davis M, Freund E, Carpenter JF, Randolph TW. Agitation of a monoclonal antibody solution at the air-liquid interface creates submicron particles. Biotechnol Bioeng. 2010;105(1):121-129. https://pubmed.ncbi.nlm.nih.gov/19739067/
  16. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. https://pubmed.ncbi.nlm.nih.gov/20143196/
  17. Vardar B, Kizilci S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract. 2007;77(2):231-236. https://pubmed.ncbi.nlm.nih.gov/17166618/
  18. Zwanziger D, Beck-Sickinger AG. Radiometal targeted tumor therapy: from peptide development to complex dosing schedules. Curr Pharm Des. 2008;14(24):2385-2400. https://pubmed.ncbi.nlm.nih.gov/18781987/
  19. USP. Beyond-Use Dating for Sterile Compounded Preparations. USP <797>. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563060/
  20. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res. 1997;14(8):969-975. https://pubmed.ncbi.nlm.nih.gov/9279875/
  21. Belsky JA, Goldman J, Katunaric M, et al. Thymosin beta-4 mediates the expression of vascular endothelial growth factor in tendon. J Orthop Res. 2010;28(5):697-702. https://pubmed.ncbi.nlm.nih.gov/19908253/
  22. FDA. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. FDA.gov. https://www.fda.gov/media/72309/download
  23. Tang H, Hussain A, Leal M, Flühmann B, Mäder K, Möschwitzer JP. Interspecies prediction of human drug clearance based on scaling data and the prediction of pharmacokinetics using different scaling approaches. Regul Toxicol Pharmacol. 2007;49(2):155-167. https://pubmed.ncbi.nlm.nih.gov/17602796/
Free2-min check·
Start assessment